{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:42:40Z","timestamp":1772757760478,"version":"3.50.1"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T00:00:00Z","timestamp":1091145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>  <jats:italic>Background<\/jats:italic>:\u2002Alemtuzumab (MabCampath<jats:sup>\u00ae<\/jats:sup>; ILEX Pharmaceuticals, Geneva, Switzerland) is a humanised monoclonal antibody directed against CD52. It belongs to a new group of monoclonal antibodies with anti\u2010neoplastic effects used in chronic lymphocytic leukaemia (CLL) either as first\u2010line treatment or in those cases resistant to alkylating drugs. Paraneoplastic pemphigus (PNP) is a severe mucocutaneus disease mostly associated with B\u2010cell lymphoproliferative disorders. Independent of the course of the underlying malignancy, this disease is often resistant to conventional immunosuppressive treatment and may lead to death as a result of infectious complications. <jats:italic>Case presentation<\/jats:italic>:\u2002We report a case where an ongoing long\u2010term remission of PNP has been induced by alemtuzumab in a patient with an underlying B\u2010CLL. A 68\u2010yr\u2010old male with a 4\u2010yr history of B\u2010CLL presented with a widespread blistering eruption on the extremities and trunk and a severe stomatitis. The diagnosis of PNP relied on the clinical, histological and direct immunofluorescence findings. Despite intensive treatment strategies with various immunosuppressive drugs and antibiotics, blisters continued to develop and the patient was deteriorating. When treated with alemtuzumab the mucocutaneous lesions healed almost completely within a few weeks and the patients\u2019 general condition improved significantly. After 12\u2003wk of treatment with alemtuzumab, the CLL infiltration of the bone marrow previously quantified at 75\u201380% remitted completely. Twelve months later, the patient was still in remission with only a small residual ulceration on the lip and one on the penis. <jats:italic>Conclusions<\/jats:italic>:\u2002Based on this case report we recommend treatment with alemtuzumab to severe cases of PNP in CLL. However, further follow\u2010up of this case is needed in order to assess the long\u2010term effect of alemtuzumab treatment in PNP.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2004.00280.x","type":"journal-article","created":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T15:50:28Z","timestamp":1091202628000},"page":"206-209","source":"Crossref","is-referenced-by-count":43,"title":["Alemtuzumab\u2010induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment\u2010resistant B\u2010cell chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"73","author":[{"given":"Thomas","family":"Hohwy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Steiniche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Anker","family":"Peterslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"D'Amore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,7,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(03)00253-7"},{"key":"e_1_2_6_4_2","first-page":"77","article-title":"Paraneoplastic pemphigus","volume":"12","author":"Anhalt GJ.","year":"1997","journal-title":"Adv Dermatol"},{"key":"e_1_2_6_5_2","volume-title":"Skin Pathology","author":"Elder D.","year":"2002"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-001-0130-x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03365.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70203-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04609.x"},{"key":"e_1_2_6_10_2","first-page":"269","article-title":"Anti\u2010CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma\u2010associated paraneoplastic pemphigus","volume":"137","author":"Borradori L","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05260.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04244.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61787-X"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2004.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2004.00280.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2004.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T15:30:50Z","timestamp":1697211050000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2004.00280.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,30]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1600-0609.2004.00280.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00280.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,30]]}}}